Rat nasal lavage biomarkers to assess preclinical irritation potential of nasal drug formulations and excipients.
The goal of this study was to evaluate biomarkers of nasal mucosal damage for rapid assessment of irritancy potential of formulations in the rat nasal lavage model, a tool to facilitate nasal formulation development prior to histopathology studies. The nasal cavity of anesthetized rats was lavaged with normal saline 20 min pos-tdose. The collected fluid was analyzed for secreted total protein and biomarkers. Solutions tested include: normal saline, buffers, benzalkonium chloride (BAC), lysophosphatidylcholine (LPC), and four marketed nasal products. Total protein, lactate dehydrogenase and interleukin-1alpha biomarkers were secreted to varying degrees. BAC (0.2%) and LPC (0.5%) exhibiting the strongest response with a signal window ranging from 3.4- to 87-fold greater levels than normal saline. Buffer treatments, excipients, and most marketed nasal products yielded levels similar to normal saline. There was a weak correlation between formulation osmolarity and surface tension with any of the biomarkers. Each nasal formulation elicited a unique protein and biomarker profile with total protein secretion correlated with IL-1alpha secretion suggesting the potential for an inflammatory response. Taken together, rapid and potentially mechanistic information on the preclinical acute irritancy potential of formulations was assessed in the rat nasal lavage model by benchmarking treatments relative to controls and marketed nasal products.
Bristol-Myers Squibb Co, Exploratory Biopharmaceutics and Stability, New Brunswick, New Jersey 08903, USA. neil.mathias@bms.com
Neil R
NR
Mathias
Paul
P
Moench
Christopher
C
Heran
Munir A
MA
Hussain
Ronald L
RL
Smith
D000281:Administration, Intranasal; D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005079:Excipients / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D053582:Interleukin-1alpha / Q000378:metabolism; D007509:Irritants / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D017817:Nasal Lavage Fluid / Q000737:chemistry; D009297:Nasal Mucosa / Q000187:drug effects* / Q000378:metabolism; D009994:Osmolar Concentration; D009195:Peroxidase / Q000378:metabolism; D011506:Proteins / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013500:Surface Tension; D013997:Time Factors; D023382:Toxicity Tests, Acute
D015415:Biomarkers; D005079:Excipients; D053582:Interleukin-1alpha; D007509:Irritants; D011506:Proteins; D007770:L-Lactate Dehydrogenase; D009195:Peroxidase